You are here

New Antibiotic Shows Promise for Treating MRSA Pneumonia

Patients respond well to ceftaroline fosamil (September 11)

A drug approved 2 years ago for treating bacterial infections may hold promise for treating potentially fatal methicillin-resistant Staphylococcus aureus (MRSA) pneumonia, according to a Henry Ford Hospital study.

Researchers found that patients treated with the antibiotic ceftaroline fosamil (CPT-F) had a lower mortality rate after 28 days compared with patients treated with vancomycin, the most common drug therapy for MRSA pneumonia.

In the retrospective study, 33 of 38 patients responded well to treatments of CPT-F and were discharged from the hospital after the infection cleared. Of the five patients who died, three of the deaths were attributed to other serious medical conditions.

The mortality rate for patients treated with vancomycin has been reported to be as high as 32% after 28 days. In the new study, the mortality rate for the CPT-F–treated patients was 13%.

The study’s findings were presented Sept. 11 at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy, held in Denver.

Source: EurekAlert; September 11, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs